Hyperlipidemia
Conditions
Interventions
Control group:Zanghongqu decoction piece placebo
Test group:Zanghongqu decoction piece
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria for hyperlipidemia and have LDL-C = 3.4 mmol/L; (2) Age between 18-75 years old gender is not limited; (3) Subjects were able to understand the purpose of the clinical trial participated voluntarily and signed informed consent.
Exclusion criteria
Exclusion criteria: Subjects shall be excluded from this trial if they meet any of the following criteria: (1) Persons with secondary dyslipidemia caused by disease or medication etc; (2) Those who are using heparin thyroid therapeutic drugs and other drugs that affect lipid metabolism; (3) Patients with familial refractory hyperlipidemia; (4) Those who have been taking statin drugs or lipid-lowering related Chinese medicines/proprietary Chinese medicines for a long period of time and cannot stop taking them; (5) History of cardiovascular and cerebrovascular diseases (coronary angina myocardial infarction heart failure stroke transient ischemic attack coronary artery revascularization or other arterial revascularization); (6) Patients with peripheral arterial disease or aortic aneurysm; (7) Patients with severe hypertension (SBP =180 and/or DBP =110) severe cardiac arrhythmia (rapid atrial fibrillation complete bundle branch block etc.) type 1 diabetes mellitus and type 2 diabetes mellitus; (8) Those with abnormal liver function (ALT/AST > 1.5 times the upper limit of reference value) and abnormal kidney function (Cr > upper limit of reference value); (9) Those suffering from malignant tumors organ failure post-transplantation and other serious chronic diseases; (10) Pregnant or lactating women or those who have a request for childbirth within 3 months; (11) Long-term alcoholism drug dependence or mental illness; (12) Those who are allergic to the drugs used in this study; (13) Poor compliance withdrawal serious organ damage acute and critical illnesses and infectious diseases; (14) Patients who have participated or are participating in other drug clinical studies within the last 3 months; (15) Patients who are judged by the investigator to be unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean percent change in LDL-C from baseline to week 12; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean percentage change in TG from baseline to week 4 and week 12;Mean percentage change in TC from baseline to week 4 and week 12;Mean percent change in LDL-C from baseline to week 4;Mean percentage change in blood homocysteine from baseline to weeks 4 and 12;Mean percent change in blood uric acid from baseline to weeks 4 and 12;The proportion of patients with LDL-C reduction =30% compared with baseline at 12 weeks of treatment;Mean percentage change in non-HDL-C from baseline to weeks 4 and 12;Mean percentage change in HDL-C from baseline to week 4 and week 12;Mean percent change in fasting insulin from baseline to weeks 4 and 12;Mean percent change in fasting glucose from baseline to weeks 4 and 12; | — |
Countries
China
Contacts
Public ContactZhu Mingjun
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed